Genfit (GNFTF) - OTCPK - Current
  • Wed, Apr. 6, 1:45 PM
    | Wed, Apr. 6, 1:45 PM | 19 Comments
  • Mar. 26, 2015, 4:21 PM
    • Investors showed Intercept Pharmaceutics (NASDAQ:ICPT) some love today. Shares jumped 8% on triple normal volume in apparent response to potential competitor Genfit's (OTCPK:GNFTF) presentation of results from a Phase 2 trial of its candidate for the treatment of nonalcoholic steatohepatitis (NASH), GFT505, in a way that would make a politician proud.
    • The randomized study, called GOLDEN-505, failed. The culprit was a group of early NASH patients (NAFLD Activity Score (NAS) = 3). This group, with its shockingly high placebo response rate of >57%, ruined the trial. Not to worry, though, because the problem was easily fixed by excluding the group. Using the magic of statistics on the revised population of NASH patients with NAS scores >= 4, the trial met its primary endpoint both in the global (n=274) (p=0.016) and evaluable (n=237) (p=0.027) populations, although what the specific endpoint actually was is not specified. Also, the number of responders was almost double placebo (22.4% vs. 12.7%; p=0.046).
    • Genfit plans to advance GFT505 to Phase 3 development.
    | Mar. 26, 2015, 4:21 PM | 30 Comments
Company Description
Genfit is a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions to address high unmet patient needs in metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology.
Country: France